(Published March 2011)
Accreditation, Publication Information, and Post-Test
At the conclusion of this activity, participants should be able to:
- Describe emergency contraception (EC) products, regimens, and access issues to ensure more consistent usage by patients.
- Outline and discuss mechanism of action of EC with patients as a means of dispelling myths surrounding these products.
- Respond to patients' concerns about the safety and efficacy of EC products using FDA guidelines.
- Provide evidence-based EC information and appropriate counseling and care to patients to ensure improved patient health care outcomes.
This clinical monograph is supported by an educational grant from Teva Pharmaceuticals.
Linda Dominguez, RN-C, NP
Donald F. Downing, RPh
Eleanor B. Schwarz, MD, MS
James Trussell, BPhil, PhD
Elizabeth Westley, MPH
ARHP acknowledges James Trussell, PhD, professor of economics and public affairs and director, Office of Population Research at Princeton University, and Elizabeth G. Raymond, MD, MPH, associate medical director, Family Health International, for developing the significant original content of this monograph.
Contributing Staff and Consultants
Shana Brown, MPH, associate director of development
Elizabeth Callihan, consulting designer
Ellen L. Cohen, Cert. Ed., Dip.Ed., CCMEP, director of education
Camille V. Harris, MPH, program manager
Beth Jordan, MD, medical director
Deborah Kurnik, MBA, consulting writer
Rebecca Sager, director of development
Wayne C. Shields, ARHP president and CEO
Financial Disclosure Information
Downing, Schwarz, Trussell, Westley, Brown, Callihan, Cohen, Harris, Jordan, Kurnik, Sager, and Shields have nothing to disclose.
The following committee members and/or contributing staff have a financial interest or affiliation with the manufacturers of commercial products possibly related to topics covered in this issue of Clinical Proceedings®
. These financial interests or affiliations are in the form of grants, research support, speaker support, or other support. This support is noted to fully inform readers and should not have an adverse impact on the information provided within this publication.
Dominguez: Consultant/Speaker for Teva/Barr, Wyeth, Schering Plough.
Participants who correctly answer at least 70% of the post-test questions will receive continuing education credit. If you have any questions, please contact ARHP staff at (202) 466-3825 or email@example.com. You will receive a certificate of completion within four weeks of submitting the post-test.
Nurses and Nurse PractitionersThis activity has been approved by the Continuing Education Approval Program of the National Association of Nurse Practitioners in Women's Health for 2 contact hours, including 1.0 pharmacology hour. Credit can be applied toward the nursing continuing education requirements of most professional organizations and state Boards of Nursing.
Nurse MidwivesAMA PRA Category 1 Credits are accepted by the Continuing Competency Assessment Program of the American College of Nurse Midwives for programs relevant to nurse midwifery. Nurse Midwives who complete this activity may report up to 2 hours of credit.
Pharmacistswww.arhp.org/EC-PharmCredits to access the accredited monograph for pharmacists, co-sponsored by the American Pharmacists Association (APhA) (free for APhA members; $15 for non-members).
The Association of Reproductive Health Professionals is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
ARHP designates this enduring material for a maximum of 2.0 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physician Assistants The American Academy of Physician Assistants accepts AMA PRA Category 1 Credits from organizations accredited by the Accreditation Council for Continuing Medical Education. Physician Assistants who complete this activity may report up to 2 credits.